Navigation Links
Endo Reports First Quarter Financial Results
Date:5/7/2013

ry levels and the anticipated timing of future product launches and events. The company's guidance for reported (GAAP) earnings per share does not include any estimates for potential new corporate development transactions. For the full twelve months ended Dec. 31, 2013, at current exchange rates, Endo estimates:

  • Total revenue to be between $2.80 billion and $2.95 billion
  • Reported (GAAP) diluted earnings per share to be between $2.10 and $2.40
  • Adjusted diluted earnings per share to be between $4.40 and $4.70
  • The company's 2013 guidance is based on certain assumptions including:

  • Adjusted gross margin of between 64 percent and 66 percent
  • Adjusted effective tax rate of between 28.5 percent and 29.5 percent
  • The company assumes the availability of a non-AB rated, full-line generic extended-release oxymorphone for the first six months of 2013. The company further assumes no generic competition thereafter due to the anticipated outcome of an FDA decision in May 2013 that could remove generic formulations of non-tamper-resistant extended-release oxymorphone from the market. Consistent with its Citizen's Petition, the company continues to believe that sufficient evidence exists to support a determination by FDA that the old formulation of OPANA ER was discontinued for reasons of safety, which serves the public health. The company's expected revenues for 2013 reflect a reduction in 2013 OPANA ER net sales of 20% versus 2012 net sales, due to the effect of potential erosion in market share from the single, non-AB-rated generic competitor that launched in Jan. 2013 combined with the impact of recent prescription trends reflecting flat market share.
  • The company continues to expect a single generic competitor for LIDODERM in September 2013 as a result of a previously announced settlement agreement with Actavis (formerly Watson Pharmaceuticals).
  • Balance Sheet UpdateDuring the first quarter of 2013,
    '/>"/>

    SOURCE Endo Health Solutions
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    8. Luminex Corporation Reports First Quarter 2012 Results
    9. Hospira Reports First-Quarter 2012 Results
    10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
    11. The Female Health Company Reports Second Quarter Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
    (Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
    (Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
    Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
    ... a new market research report is available in its ... Market Report: 2010 Edition http://www.reportlinker.com/p0304775/Global-In-Vitro-Diagnostics-IVD-Market-Report-2010-Edition.html ... been experiencing rapid growth, in spite of the economic ... prevention of diseases among the people, which is expected ...
    ... today announced that industry veteran Glenn Kazo has assumed the ... capacities with Prolong since 2007. He succeeds Prolong founder Dr. ... have known Glenn for more than thirty years," said Dr. ... "I feel he is one of the greatest strategic minds ...
    Cached Medicine Technology:Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 2Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 3Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 4Reportlinker Adds Global In Vitro Diagnostics (IVD) Market Report: 2010 Edition 5Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President 2
    (Date:12/22/2014)... (PRWEB) December 22, 2014 Sagacious Consultants, ... add a subscription option to their ad hoc report ... writing services. Customers can sign up for an annual ... hours each month at a deeply discounted hourly rate. ... and each has a progressively discounted rate. Subscription hours ...
    (Date:12/22/2014)... Dec. 19, 2014 (HealthDay News) -- U.S. and state ... caramel apples that has killed at least four people ... should not eat any commercially produced, prepackaged caramel apples ... Disease Control and Prevention said in a news release. ... people had been infected with the outbreak strains of ...
    (Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
    (Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
    (Date:12/22/2014)... Christmas is days away, and last minute ... easy solution that will please: the Sublime Gift Card ... from $25 up to $350," says Kathy Heshelow, founder of ... a wide array of skin care products and Skin Brushes." ... dates. , Gift delivery past shipping deadlines, or those ...
    Breaking Medicine News(10 mins):Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
    ... Calif., July 8 ChemoCentryx, Inc. today announced ... Officer, will give a keynote lecture at The 9th World ... "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and ... given on Thursday, July 9, 2009 at 9:00 am local ...
    ... Save Roughly $3,000 A Year By Switching From Expensive Brand ... Hyperactivity Disorder (ADHD) , , YONKERS, N.Y., July 8 ... Buy Drugs report, parents should be skeptical if their doctors ... of attention deficit hyperactivity disorder (ADHD). Free samples can ...
    ... Switzerland, 8 July 2009 - The International Diabetes Federation ... World Heart Federation (WHF) called today on the UN,s ... to avert the fastest growing threat by non-communicable diseases ... cardiovascular disease, diabetes, cancer and chronic respiratory disease, cause ...
    ... BETHEL, Conn., July 8 MedClean Technologies, Inc. (OTC Bulletin ... to exchange all of the Company,s existing Common Stock Purchase ... August 29, 2008 ("Existing Warrants") for newly issued Common Stock ... per share, exercisable for one-half the original number of shares ...
    ... July 8 Universal Health Services, Inc. (NYSE: UHS ... its Board of Directors. He becomes the eighth member of the ... of Hayground Cove Capital Partners LLC, in New York, NY, a ... that, Mr. Silvers was a Vice President at Fortress Investment Group ...
    ... , , , HARRISBURG, Pa., July 8 ... his office, the departments of Health and Education, and the ... H1N1 Influenza Preparedness Summit in Maryland on July 9. , ... information that will be used in Pennsylvania,s ongoing efforts to ...
    Cached Medicine News:Health News:ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan 2Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 2Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 3Health News:Consumer Reports to Parents: Think Twice About Free Prescription ADHD Drug Samples for Your Children 4Health News:The next health tsunami: Noncommunicable diseases 2Health News:MedClean Technologies Announces Results of Private Exchange Offer 2Health News:Rendell Administration Officials to Participate in National Flu Summit 2
    SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
    Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
    ... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
    The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
    Medicine Products: